Literature DB >> 823117

Development of a purified cholera toxoid. III. Refinements in purification of toxin and methods for the determination of residual somatic antigen.

R S Rappaport, W A Pierzchala, G Bonde, T McCann, B A Rubin.   

Abstract

The addition of an ultrafiltration step to the purification procedures previously described for cholera toxin (Rappaport et al., (1974) permitted the preparation of highly purified antigenic toxoids essentially free of somatic antigen(s). The purity of such toxoids is established: (i) by the absence of more than about one part limulus amebocyte lysate (LAL)-positive endotoxin per 10(5) parts toxoid and (ii) by the inability of the toxoids to elicit a significant rise in rabbit vibriocidal antibody. The antigenicity of the toxoids is demonstrated by their ability to produce the same high levels of rabbit serum antitoxin as are produced by comparable toxoids containing small amounts of somatic antigen. The results also indicate that amounts of somatic antigen of the order of less than or equal to 1 mug/100 mug of toxoid do not exert an adjuvant effect on the toxoid, at least with respect to circulating antitoxin. Other data show that, where present, the ability of somatic antigen to elicit vibriocidal antibody is influenced by the immunization schedule employed and that a correlation exists between the LAL-determined endotoxin content of the toxoids and their ability to stimulate vibriocidal antibody. Somatic antigen-free toxoids, purified and tested by the refinements herein described, were prepared for use in the National Institutes of Health sponsored field trials, and data pertaining to their purity and antigenic properties are presented.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 823117      PMCID: PMC420941          DOI: 10.1128/iai.14.3.687-693.1976

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  5 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Picogram-sensitive assay for endotoxin: gelation of Limulus polyphemus blood cell lysate induced by purified lipopolysaccharides and lipid A from Gram-negative bacteria.

Authors:  E T Yin; C Galanos; S Kinsky; R A Bradshaw; S Wessler; O Lüderitz; M E Sarmiento
Journal:  Biochim Biophys Acta       Date:  1972-01-28

3.  Development of a purified cholera toxoid. II. Preparation of a stable, antigenic toxoid by reaction of purified toxin with glutaraldehyde.

Authors:  R S Rappaport; G Bonde; T McCann; B A Rubin; H Tint
Journal:  Infect Immun       Date:  1974-02       Impact factor: 3.441

4.  A permeability factor (toxin) found in cholera stools and culture filtrates and its neutralization by convalescent cholera sera.

Authors:  J P Craig
Journal:  Nature       Date:  1965-08-07       Impact factor: 49.962

5.  Development of a purified cholera toxoid. I. Purification of toxin.

Authors:  R S Rappaport; B A Rubin; H Tint
Journal:  Infect Immun       Date:  1974-02       Impact factor: 3.441

  5 in total
  9 in total

1.  Antigenicity of purified glutaraldehyde-treated cholera toxoid administered orally.

Authors:  M M Levine; T P Hughes; C R Young; S O'Donnell; J P Craig; H P Holley; E J Bergquist
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

2.  Suppression of local intestinal immunoglobulin A immune response to cholera toxin by subcutaneous administration of cholera toxoids.

Authors:  S R Hamilton; J H Yardley; G D Brown
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

3.  Protection against experimental cholera by oral or parenteral immunization.

Authors:  J W Peterson
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

Review 4.  New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.

Authors:  M M Levine; J B Kaper; R E Black; M L Clements
Journal:  Microbiol Rev       Date:  1983-12

5.  Improved protection against cholera in adult rabbits with a combined flagellar-toxoid vaccine.

Authors:  I G Resnick; C W Ford; G M Shackleford; L J Berry
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

6.  Both cholera toxin-induced adenylate cyclase activation and cholera toxin biological activity are inhibited by antibodies against related synthetic peptides.

Authors:  C O Jacob; M Sela; M Pines; S Hurwitz; R Arnon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

7.  Synergistic protection against experimental cholera by immunization with cholera toxoid and vaccine.

Authors:  J W Peterson
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

8.  Induction of a mucosal antitoxin response and its role in immunity to experimental canine cholera.

Authors:  N F Pierce; W C Cray; B K Sircar
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

9.  Development of a vaccine against experimental cholera and Escherichia coli diarrheal disease.

Authors:  R S Rappaport; G Bonde
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.